



Supplementary Figure S1. Study flow chart.

Supplementary Table S1. Subgroup analyses of serum Lp-PLA2 associations with stroke, MACE, and all-cause death

Characteristics	Quartile 1		Quartile 2		Quartile 3		Quartile 4		P for interaction
	n, %	HR (95% CI)	n, %	HR (95% CI)	n, %	HR (95% CI)	n, %	HR (95% CI)	
Stroke									
Gender									
Males	20 (1.3)	Reference	26 (1.7)	1.41 (0.70–2.84)	37 (2.5)	1.57 (0.80–3.09)	28 (1.9)	1.98 (0.96–4.08)	0.36
Females	2 (0.4)	Reference	4 (0.8)	5.65 (0.59–54.1)	8 (1.5)	2.00 (0.30–13.1)	12 (2.2)	5.68 (0.62–52.5)	
Age (years)									
< 65	16 (1.2)	Reference	22 (1.6)	1.05 (0.50–2.19)	26 (1.9)	1.05 (0.52–2.13)	16 (1.2)	1.37 (0.58–3.25)	0.06
≥ 65	6 (0.9)	Reference	8 (1.2)	2.02 (0.39–12.6)	19 (2.9)	1.35 (0.20–9.04)	24 (3.7)	2.26 (0.42–12.1)	
hs-CRP (mg/dL)									
< 1.0	10 (1.1)	Reference	11 (1.2)	2.95 (1.09–8.00)	20 (2.2)	1.42 (0.56–3.59)	15 (1.7)	2.86 (1.03–7.94)	0.07
≥ 1.0	12 (1.1)	Reference	19 (1.7)	2.19 (0.84–5.73)	25 (2.2)	2.19 (0.85–5.68)	25 (2.2)	2.64 (1.03–6.78)	
MACE									
Gender									
Males	27 (1.8)	Reference	39 (2.6)	1.21 (0.70–2.09)	46 (3.1)	1.47 (0.85–2.57)	37 (2.5)	1.90 (1.05–3.44)	0.10
Females	4 (0.8)	Reference	4 (0.8)	1.32 (0.25–7.01)	8 (1.5)	0.50 (0.11–2.33)	15 (2.8)	0.50 (0.10–2.66)	
Age (years)									
< 65	25 (1.8)	Reference	33 (2.3)	1.05 (0.58–1.92)	29 (2.1)	0.98 (0.54–1.78)	20 (1.5)	1.16 (0.57–2.36)	0.05
≥ 65	6 (0.9)	Reference	11 (1.7)	2.32 (0.54–9.92)	25 (3.9)	3.19 (0.68–15.0)	32 (4.9)	4.31 (1.01–18.4)	
hs-CRP (mg/dL)									
< 1.0	13 (1.4)	Reference	16 (1.8)	1.88 (0.79–4.46)	23 (2.5)	1.57 (0.70–3.53)	20 (2.2)	1.54 (0.67–3.54)	0.06
≥ 1.0	18 (1.6)	Reference	27 (2.4)	1.26 (0.62–2.58)	31 (2.8)	1.44 (0.68–3.08)	32 (2.9)	2.08 (0.98–4.40)	
All-cause death									
Gender									
Males	21 (1.4)	Reference	35 (2.3)	1.46 (0.80–2.71)	56 (3.8)	1.67 (0.93–2.98)	93 (6.2)	2.26 (1.27–4.03)	0.04
Females	7 (1.3)	Reference	2 (0.4)	3.99 (0.45–35.3)	10 (1.9)	1.84 (0.45–7.49)	17 (3.2)	1.78 (0.53–5.98)	
Age (years)									
< 65	15 (1.1)	Reference	12 (0.9)	1.28 (0.49–3.30)	18 (1.3)	0.92 (0.40–2.15)	17 (1.2)	2.18 (0.88–5.37)	0.30
≥ 65	13 (2.0)	Reference	25 (3.9)	2.09 (0.95–4.60)	48 (7.4)	2.44 (1.15–5.16)	93 (14.4)	2.27 (1.10–4.70)	
hs-CRP (mg/dL)									
< 1.0	7 (0.8)	Reference	14 (1.5)	1.46 (0.39–5.46)	22 (2.4)	1.09 (0.31–3.86)	30 (3.3)	2.05 (0.57–7.35)	0.08
≥ 1.0	21 (1.9)	Reference	23 (2.1)	1.64 (0.85–3.15)	44 (3.9)	2.02 (1.11–3.65)	80 (7.1)	2.13 (1.20–3.79)	

Note. Adjustments made for age, gender, body mass index (BMI), drinker status, smoking status, history of hypertension, hyperlipidemia, diabetes, and hs-CRP. Bold HR (95% CI) and P value indicate statistical significance.